July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
New Paper Alert: Perioperative Chemoimmunotherapy In Resectable Stage II–IIIA NSCLC – OncoDaily IO
Jul 30, 2025, 17:50

New Paper Alert: Perioperative Chemoimmunotherapy In Resectable Stage II–IIIA NSCLC – OncoDaily IO

OncoDaily IO shared a post on LinkedIn:

“New Paper Alert – JAMA Network Open.

Real-world data confirms: Perioperative chemoimmunotherapy significantly improves 18-month distant metastasis-free survival (DMFS) in resectable stage II-IIIA NSCLC.

Yet in 2023, <30% of eligible patients received it.

Key Study Highlights:

  • N = 1,334 | Flatiron Health EHR database
  • DMFS:
  • Neoadjuvant: 80.2%
  • Adjuvant: 83.0%
  • DMFS ≥95% when ≥12 months of adjuvant immunotherapy is completed

Challenges Identified:

  • Underutilization in real-world settings
  • Suboptimal biomarker testing (<60% in neoadjuvant cohort)
  • Variability in treatment duration

Urgent need for:

  • Improved biomarker testing workflows
  • Greater multidisciplinary uptake

Read the full study: Desai et al, JAMA Network Open, June 2025.

Summary.

OncoDaili IO